Nexus Spine’s patented Tranquil spinal interbody implants saw strong outcomes in early data, according to a Sept. 11 news release.
A pilot study assessed Tranquil in anterior cervical discectomy and fusion patients who were older than 66 years of age, had poor bone quality or needed cervical fusion at at least three contiguous levels. Radiographic assessments were taken at two weeks, six weeks, six months and a year.
Researchers found spinal levels treated with Tranquil had no measurable subsidence, but other interbody devices had demonstrated measurable subsidence as early as two weeks in more than 66% of levels treated.
“If we can solve the key challenges for the highest-risk patients then we can improve the universal standard of care,” Nexus Spine President David Hawkes said in the release. “Matching the stiffness of the host bone is key. This pilot study is very exciting because it demonstrates that our patented Tranquil interbody implants are better at preventing subsidence. We are also looking at how much faster our devices provide stability. Subsidence and prolonged instability are both consequences of using an interbody that is too stiff.”
